BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24556620)

  • 1. Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1.
    Akashi Y; Oda T; Ohara Y; Miyamoto R; Kurokawa T; Hashimoto S; Enomoto T; Yamada K; Satake M; Ohkohchi N
    Br J Cancer; 2014 Mar; 110(6):1481-7. PubMed ID: 24556620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling.
    Gong JH; Zheng YB; Zhang MR; Wang YX; Yang SQ; Wang RH; Miao QF; Liu XJ; Zhen YS
    Cancer Biol Ther; 2020 Apr; 21(4):332-343. PubMed ID: 31906826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts.
    Nakahira S; Nakamori S; Tsujie M; Takeda S; Sugimoto K; Takahashi Y; Okami J; Marubashi S; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Anticancer Res; 2008; 28(1A):179-86. PubMed ID: 18383843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase.
    Roman NO; Samulitis BK; Wisner L; Landowski TH; Dorr RT
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):183-92. PubMed ID: 20339847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
    Rajeshkumar NV; De Oliveira E; Ottenhof N; Watters J; Brooks D; Demuth T; Shumway SD; Mizuarai S; Hirai H; Maitra A; Hidalgo M
    Clin Cancer Res; 2011 May; 17(9):2799-806. PubMed ID: 21389100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
    Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
    Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine.
    Luo D; Digiovanni MG; Wei R; Lacomb JF; Williams JL; Rigas B; Mackenzie GG
    Carcinogenesis; 2020 Jul; 41(7):927-939. PubMed ID: 31584613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
    Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
    Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine potentiates anti-tumor effect of resveratrol on pancreatic cancer via down-regulation of VEGF-B.
    Yang Y; Tian W; Yang L; Zhang Q; Zhu M; Liu Y; Li J; Yang L; Liu J; Shen Y; Qi Z
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):93-103. PubMed ID: 32897433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quercetin induces apoptosis and enhances gemcitabine therapeutic efficacy against gemcitabine-resistant cancer cells.
    Liu ZJ; Xu W; Han J; Liu QY; Gao LF; Wang XH; Li XL
    Anticancer Drugs; 2020 Aug; 31(7):684-692. PubMed ID: 32282368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
    Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
    Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway.
    Liu Y; Bi T; Liu L; Gao Q; Shen G; Qin L
    Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):615-622. PubMed ID: 30683944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
    Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
    J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells.
    Koga H; Selvendiran K; Sivakumar R; Yoshida T; Torimura T; Ueno T; Sata M
    Int J Oncol; 2012 Mar; 40(3):679-85. PubMed ID: 22020928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines.
    Morimoto Y; Takeuchi O; Takizawa A; Yoneyama H; Asanuma F; Suzuki Y; Atsuda K; Yamada Y
    Anticancer Drugs; 2012 Jun; 23(5):505-14. PubMed ID: 22334000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway.
    Xiang Y; Ye W; Huang C; Yu D; Chen H; Deng T; Zhang F; Lou B; Zhang J; Shi K; Chen B; Zhou M
    Oxid Med Cell Longev; 2018; 2018():2360427. PubMed ID: 29849873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.
    Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
    Mol Cancer Ther; 2012 Dec; 11(12):2644-53. PubMed ID: 23047891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.
    Awasthi N; Kirane A; Schwarz MA; Toombs JE; Brekken RA; Schwarz RE
    BMC Cancer; 2011 Jan; 11():15. PubMed ID: 21226944
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Yang H; Tong Z; Shen L; Sun YU; Hoffman RM; Huang J
    Anticancer Res; 2020 Sep; 40(9):4969-4978. PubMed ID: 32878785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
    Awasthi N; Schwarz MA; Schwarz RE
    HPB (Oxford); 2011 Sep; 13(9):597-604. PubMed ID: 21843259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.